PharmaEssentia Corporation PharmaEssentia Corporation

PharmaEssentia Corporation

6446

Peringkat dalam Saham #1418
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Harga Saham
$37.84
Kapitalisasi Pasar
$15.65B
Perubahan (1 hari)
-4.42%
Perubahan (1 tahun)
149.23%
Negara
TW
Perdagangan PharmaEssentia Corporation (6446)

Kategori

Healthcare
Riwayat dividen untuk PharmaEssentia Corporation (6446)
Saham PharmaEssentia Corporation (simbol: 6446) telah membayar total 1 dividen.
Total semua dividen (disesuaikan dengan stock split): $0.99
Imbal hasil dividen (TTM): 0.0012
Pembayaran dividen untuk PharmaEssentia Corporation (6446) dari 2025 hingga 2026
Pembayaran dividen tahunan
Tahun Dividen (disesuaikan dengan stock split) Mengubah
2026 (TTM) $0.9898 0.00%
2025 $0.9898 0.00%
Daftar semua pembayaran dividen
Tahun Dividen Mengubah
2026 (TTM) $1.10 0.00%
2025 $1.10 0.00%
Pembayaran dividen untuk perusahaan sejenis atau pesaing